Role of PET/CT in Renal Cell Carcinoma
CT stages the kidney. FDG earns its place with the equivocal recurrence, not the primary.
Multiphasic contrast-enhanced CT of the chest and abdomen is the standard test for diagnosing and staging renal cell carcinoma (RCC). MRI answers selected questions, such as venous involvement or an indeterminate mass. 18F-FDG PET/CT is not recommended for primary staging or for routine follow-up.
Why FDG is limited
- Urinary excretion. FDG in the renal parenchyma and collecting system can obscure a primary tumour.
- Variable uptake. Many RCCs take up little FDG. For the primary renal lesion, pooled sensitivity of FDG PET is only 62%, so a negative scan cannot exclude disease.
- The guidelines follow. The EAU advises against FDG PET/CT, and bone scan, for primary staging, and against routine PET in follow-up because of limited sensitivity and specificity.
Where FDG PET/CT may help
- Equivocal recurrence or metastasis. It may clarify a CT or MRI finding when the answer would change management.
- Treatment response and prognosis. In selected patients with FDG-avid disease it can add information. In metastatic clear-cell RCC on sunitinib, a high baseline SUVmax and more PET-positive lesions predicted shorter survival. Progression on FDG PET at 16 weeks predicted worse outcome; an early metabolic response at 4 weeks did not.
- This is not a routine indication.
Pearl
FDG PET in RCC is a problem-solver for a specific question, never a staging default. A negative scan does not clear the kidney.
Reported diagnostic accuracy
| Setting | Sensitivity | Specificity |
|---|---|---|
| Primary renal lesions, FDG PET | 62% | 88% |
| Extra-renal lesions, FDG PET/CT | 91% | 88% |
| Restaging, pooled FDG PET or PET/CT (per patient) | 86% | 88% |
The first two rows come from one meta-analysis of 14 studies, the third from a separate meta-analysis of 14 studies in 1168 patients. They are not a direct comparison, and the primary-lesion estimate is for PET, not PET/CT.
Other PET tracers
| Tracer | Target | Potential role |
|---|---|---|
| ⁸⁹Zr-girentuximab | Carbonic anhydrase IX | Identify clear-cell RCC in an indeterminate renal mass (phase 3: sensitivity 85.5%, specificity 87.0%) |
| PSMA PET tracers | Tumour neovasculature | Image selected RCC lesions, particularly metastatic clear-cell disease (pooled lesion detection 83%, 152 patients) |
These are evolving applications, not routine tests for all RCC. The EAU notes that they still lack external validation.
Pitfalls
- False negatives. Low-uptake tumours and small lesions may be missed.
- False positives. Inflammation takes up FDG and can mimic tumour.
- Interpretation. Accuracy depends on the question: a primary renal mass, extra-renal disease or restaging.
Take home
- Multiphasic contrast-enhanced CT stages RCC; MRI answers selected questions such as venous involvement.
- FDG PET/CT is not for primary staging or routine follow-up: urinary excretion and variable uptake limit it, and a negative scan does not exclude disease.
- Use it to resolve an equivocal recurrence or metastasis when the answer will change management; CAIX and PSMA imaging are promising but not yet routine.
Sources
- European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2026 edition. Arnhem: EAU Guidelines Office; 2026. Available from: https://uroweb.org/guidelines/renal-cell-carcinoma
- Rowe SP, Shuch BM, Ball MW, et al. SNMMI/EANM/ACNM procedure standard/procedure guideline on the use of molecular imaging for renal mass characterization. J Nucl Med. 2025;66(12):1863-70.
- Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12(3):464-74.
- Ma H, Shen G, Liu B, et al. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38(2):156-63.
- Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011;17(18):6021-8.
- Shuch B, Pantuck AJ, Bernhard JC, et al. [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(10):1277-87.
- Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med. 2024;65(7):1007-12.